Pyxis Oncology Inc Dossier
Qualitative Analysis
Business overview
Pyxis Oncology, Inc. is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers. The company's pipeline includes antibody-drug conjugates (ADCs) and immuno-oncology (IO) monoclonal antibodies designed to target the tumor microenvironment. Its lead product candidate is micvotabart pelidotin (MICVO, formerly PYX-201), a first-in-concept non-internalizing ADC targeting extradomain-B fibronectin (EDB+FN). EDB+FN is highly expressed in the extracellular matrix of various solid tumors but minimally present in normal tissues. Pyxis is also developing PYX-106, a fully human monoclonal antibody targeting Siglec-15, and other preclinical assets.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing clinical development of lead Antibody-Drug Conjugate (ADC) candidate micvotabart pelidotin (MICVO, formerly PYX-201) as both monotherapy and in combination with pembrolizumab, while pausing other programs like PYX-106 to conserve cash.
Expected impact: Establish proof-of-concept, optimize dosing approaches (dose capping and adjusted ideal body weight), and advance toward registrational trials.
Monetizing non-core royalty rights acquired through the Apexigen transaction to generate non-dilutive funding for the MICVO clinical program.
Expected impact: Generated $8.0 million from Novartis for Beovu royalty rights in early 2024 and $11.0 million upfront from Simcere for Enzeshu royalty rights in December 2025, extending the operational runway.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquire the APXiMAB antibody-discovery platform to complement Pyxis's FACT ADC toolkit, add the Phase 2 candidate sotigalimab (PYX-107), and secure royalty streams for Enzeshu and Beovu.
Financial impact: All-stock transaction valued at approximately $10.7 million at close. Provided royalty rights that were later sold for $19.0 million in aggregate cash.
Strategic Partnerships
Enables the evaluation of MICVO in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with R/M HNSCC.
Terms: Merck supplies pembrolizumab for the Phase 1/2 combination study (PYX-201-102), sharing development risk and validating Pyxis's therapeutic approach.